source
- Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competitionMarrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…
- Cardinal Health advises correction of Presource kits containing recalled BD Alaris infusion setsCardinal Health has issued a correction notice for its Presource convenience kits that include BD Alaris pump infusion sets that were previously recalled. The FDA classifies this recall as the mos…